NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $18.65 -0.10 (-0.51%) As of 11:14 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About DBV Technologies Stock (NASDAQ:DBVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DBV Technologies alerts:Sign Up Key Stats Today's Range$18.32▼$18.7550-Day Range$18.75▼$23.5452-Week Range$7.53▼$26.18Volume32,381 shsAverage Volume294,782 shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$40.25Consensus RatingModerate Buy Company Overview DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies. The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy. Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge. Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases. AI Generated. May Contain Errors. Read More DBV Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreDBVT MarketRank™: DBV Technologies scored higher than 46% of companies evaluated by MarketBeat, and ranked 426th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialDBV Technologies has a consensus price target of $40.25, representing about 118.4% upside from its current price of $18.43.Amount of Analyst CoverageDBV Technologies has only been the subject of 3 research reports in the past 90 days.Read more about DBV Technologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.47) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.31% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 9.08.Change versus previous monthShort interest in DBV Technologies has recently increased by 14.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for DBV Technologies this week, compared to 3 articles on an average week.Search Interest3 people have searched for DBVT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have not sold or bought any company stock.Percentage Held by Insiders1.06% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DBVT Stock News HeadlinesDBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 18 at 4:35 AM | americanbankingnews.comCombined General Meeting of June 3, 2026May 13, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 19 at 1:00 AM | Brownstone Research (Ad)DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving Average - Time to Sell?May 13, 2026 | americanbankingnews.comDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqMay 12, 2026 | globenewswire.comDBV Technologies Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comDBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN RevenueApril 17, 2026 | seekingalpha.comDBV Technologies SA - Depositary Receipt (DBVT) price target increased by 32.54% to 31.33April 17, 2026 | msn.comSee More Headlines DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $19.17 at the start of the year. Since then, DBVT stock has decreased by 3.9% and is now trading at $18.43. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) announced its earnings results on Thursday, April, 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.42. The business had revenue of $0.90 million for the quarter, compared to analysts' expectations of $1.11 million. DBV Technologies had a negative trailing twelve-month return on equity of 129.88% and a negative net margin of 2,895.37%. When did DBV Technologies' stock split? DBV Technologies shares reverse split on Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did DBV Technologies IPO? DBV Technologies (DBVT) raised $93 million in an initial public offering (IPO) on Wednesday, October 22nd 2014. The company issued 4,277,826 shares at a price of $21.64 per share. Who are DBV Technologies' major shareholders? Top institutional investors of DBV Technologies include ADAR1 Capital Management LLC (1.71%), Redmile Group LLC (0.83%), Atika Capital Management LLC (0.49%) and Elmind Capital LP (0.45%). Insiders that own company stock include Bpifrance Epic, Pharis Mohideen, Daniel B Soland, Timothy E Morris and Adora Ndu. View institutional ownership trends. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings4/30/2026Today5/19/2026H.C. Wainwright 4th Annual BioConnect Investor Conference5/19/2026AGM 20266/03/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DBVT's financial health is in the Green zone, according to TradeSmith. DBVT has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees80Year Founded2002Price Target and Rating Average Price Target for DBV Technologies$40.25 High Price Target$55.00 Low Price Target$7.25 Potential Upside/Downside+117.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.95 million Net Margins-2,895.37% Pretax Margin-2,883.06% Return on Equity-129.88% Return on Assets-88.84% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual Sales$5.64 million Price / Sales194.75 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book4.42Miscellaneous Outstanding Shares59,210,000Free Float58,580,000Market Cap$1.10 billion OptionableOptionable Beta-0.96 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:DBVT) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
